Mycobacterium tuberculosis PPE family protein PPE18 (Mtb39A) (Mtb39A)

Mycobacterium tuberculosis Mtb39A, also known as PPE18 (Rv1196), is a 39-kDa protein belonging to the PPE family, which is characterized by a conserved N-terminal Pro-Pro-Glu motif and is often associated with the mycobacterial cell wall or secretion systems [1][2]. This protein plays a significant role in host-pathogen interactions, specifically by binding to the host Toll-like receptor 2 (TLR2) on macrophages, which triggers an intracellular signaling cascade that can modulate the host's immune response [3]. While it may assist the bacterium in immune evasion by inducing anti-inflammatory cytokines like IL-10, its high immunogenicity makes it a valuable target for vaccine development [2][4]. Mtb39A is a critical component of the M72/AS01E recombinant fusion protein vaccine, which has shown promise in Phase IIb clinical trials for preventing active tuberculosis in individuals with latent infection [4]. In these vaccine formulations, Mtb39A serves as an antigen to stimulate CD4+ T-cell responses and the production of Th1 cytokines such as interferon-gamma and TNF-alpha [4][5]. Beyond its use in vaccines, Mtb39A is also studied for its potential as a diagnostic marker to differentiate between various stages of tuberculosis infection [5].

Other names

PPE18Rv119639 kDa antigenMtb39

Mtb39A acts as a subunit antigen in recombinant vaccines designed to elicit a robust Th1-type cellular immune response, characterized by the production of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2) by CD4+ T cells [4][5].